Overcoming cancer cell resistance to VSV oncolysis with JAK1/2 inhibitors
Published 2013 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Overcoming cancer cell resistance to VSV oncolysis with JAK1/2 inhibitors
Authors
Keywords
-
Journal
CANCER GENE THERAPY
Volume 20, Issue 10, Pages 582-589
Publisher
Springer Nature
Online
2013-09-13
DOI
10.1038/cgt.2013.55
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Neuroattenuation of Vesicular Stomatitis Virus through Picornaviral Internal Ribosome Entry Sites
- (2013) A. Ammayappan et al. JOURNAL OF VIROLOGY
- LDL receptor and its family members serve as the cellular receptors for vesicular stomatitis virus
- (2013) D. Finkelshtein et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Potent systemic therapy of multiple myeloma utilizing oncolytic vesicular stomatitis virus coding for interferon-β
- (2012) S Naik et al. CANCER GENE THERAPY
- Ruxolitinib: The First FDA Approved Therapy for the Treatment of Myelofibrosis
- (2012) J. Mascarenhas et al. CLINICAL CANCER RESEARCH
- Biology and Clinical Management of Myeloproliferative Neoplasms and Development of the JAK Inhibitor Ruxolitinib
- (2012) J. Mascarenhas et al. CURRENT MEDICINAL CHEMISTRY
- Jakinibs: a new class of kinase inhibitors in cancer and autoimmune disease
- (2012) Apostolos Kontzias et al. CURRENT OPINION IN PHARMACOLOGY
- Ruxolitinib, an oral JAK1 and JAK2 inhibitor, in myelofibrosis
- (2012) Kris Vaddi et al. EXPERT OPINION ON PHARMACOTHERAPY
- Vesicular stomatitis virus as a flexible platform for oncolytic virotherapy against cancer
- (2012) E. Hastie et al. JOURNAL OF GENERAL VIROLOGY
- Molecular phenotype predicts sensitivity of squamous cell carcinoma of the head and neck to epidermal growth factor receptor inhibition
- (2012) Natalie R. Young et al. Molecular Oncology
- Oncolytic virotherapy
- (2012) Stephen J Russell et al. NATURE BIOTECHNOLOGY
- Resistance of pancreatic cancer cells to oncolytic vesicular stomatitis virus: Role of type I interferon signaling
- (2012) Megan Moerdyk-Schauwecker et al. VIROLOGY
- Histone Deacetylase Inhibitors Induce Growth Arrest and Differentiation in Uveal Melanoma
- (2011) S. Landreville et al. CLINICAL CANCER RESEARCH
- Safety and Efficacy of TG101348, a Selective JAK2 Inhibitor, in Myelofibrosis
- (2011) Animesh Pardanani et al. JOURNAL OF CLINICAL ONCOLOGY
- Vesicular Stomatitis Virus Has Extensive Oncolytic Activity against Human Sarcomas: Rare Resistance Is Overcome by Blocking Interferon Pathways
- (2011) J. C. Paglino et al. JOURNAL OF VIROLOGY
- p37δ is a new isoform of PI3K p110δ that increases cell proliferation and is overexpressed in tumors
- (2011) S Fransson et al. ONCOGENE
- Vesicular stomatitis virus oncolysis is potentiated by impairing mTORC1-dependent type I IFN production
- (2010) T. Alain et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Lesion Development and Replication Kinetics During Early Infection in Cattle Inoculated With Vesicular Stomatitis New Jersey Virus Via Scarification and Black Fly (Simulium vittatum) Bite
- (2010) J. L. Reis et al. VETERINARY PATHOLOGY
- Novel high-throughput screening system for identifying STAT3–SH2 antagonists
- (2009) Yutaka Uehara et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- Engineering oncolytic viruses to exploit tumor specific defects in innate immune signaling pathways
- (2009) Shruthi Naik et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- Safety Studies on Intrahepatic or Intratumoral Injection of Oncolytic Vesicular Stomatitis Virus Expressing Interferon-β in Rodents and Nonhuman Primates
- (2009) Nathan Jenks et al. HUMAN GENE THERAPY
- Histone Deacetylase Inhibitors in Cancer Therapy
- (2009) Andrew A. Lane et al. JOURNAL OF CLINICAL ONCOLOGY
- Attenuation of Vesicular Stomatitis Virus Encephalitis through MicroRNA Targeting
- (2009) E. J. Kelly et al. JOURNAL OF VIROLOGY
- The Identification of 2-(1H-Indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine (GDC-0941) as a Potent, Selective, Orally Bioavailable Inhibitor of Class I PI3 Kinase for the Treatment of Cancer†
- (2008) Adrian J. Folkes et al. JOURNAL OF MEDICINAL CHEMISTRY
- Immune Response in the Absence of Neurovirulence in Mice Infected with M Protein Mutant Vesicular Stomatitis Virus
- (2008) M. Ahmed et al. JOURNAL OF VIROLOGY
- Early Steps of the Virus Replication Cycle Are Inhibited in Prostate Cancer Cells Resistant to Oncolytic Vesicular Stomatitis Virus
- (2008) B. L. Carey et al. JOURNAL OF VIROLOGY
- Immunology in China: the past, present and future
- (2008) Xuetao Cao NATURE IMMUNOLOGY
- Chemical targeting of the innate antiviral response by histone deacetylase inhibitors renders refractory cancers sensitive to viral oncolysis
- (2008) T. L.-A. Nguyen et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More